First-in-Human Study of TAK-280 in Participants With Solid Tumors
第1/2相
早期終了
NCT05220098
| 対象疾患 | Unresectable Locally Advanced or Metastatic Cancer |
|---|
| 相 | 第1/2相 |
|---|
| スポンサー | Takeda |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 69 名 |
|---|
| 介入（薬剤） | TAK-280 |
|---|
| 開始日 | 2022年4月21日 |
|---|
| 完了日 | 2025年7月28日 |
|---|
| 結果公開日 | 2026年7月7日 |
|---|
概要
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.
Number of Participants With Dose Limiting Toxicities (DLTs)
Cycle 1 (Cycle length=28 days) · Participants
| TAK-280, Dose A | 0 Participants |
|---|
| TAK-280, Dose B | 0 Participants |
|---|
| TAK-280, Dose C | 0 Participants |
|---|
| TAK-280, Dose D | 2 Participants |
|---|
| TAK-280, Dose E | 0 Participants |
|---|
| TAK-280, Dose F | 1 Participants |
|---|
Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs)
From start of study drug administration up to follow-up (up to 37 weeks) · Participants
| TAK-280, Dose A | 2 Participants |
|---|
| TAK-280, Dose B | 1 Participants |
|---|
| TAK-280, Dose C | 3 Participants |
|---|
| TAK-280, Dose D | 5 Participants |
|---|
| TAK-280, Dose E | 5 Participants |
|---|
| TAK-280, Dose F | 5 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。